Antibiotics (May 2021)

Community-Acquired, Extended-Spectrum β-Lactamase-Producing and Extensively Drug-Resistant <i>Escherichia coli</i> in a 28-Year-Old Pyelonephritis Patient Lacking Risk Factors

  • Connor W. Evins,
  • Caroline M. Sutton,
  • Sarah T. Withers,
  • Jennifer T. Grier,
  • Christine M. G. Schammel,
  • Steven E. Fiester

DOI
https://doi.org/10.3390/antibiotics10050533
Journal volume & issue
Vol. 10, no. 5
p. 533

Abstract

Read online

While Escherichia coli is a common cause of urinary tract infections and pyelonephritis, there are few documented cases of extended-spectrum β-lactamase (ESBL)-producing and extensively drug-resistant (XDR) isolates from the community resulting in infection requiring hospitalization, especially in individuals lacking risk factors. In the United States, exposure to ESBL-producing E. coli is typically nosocomial, whereas patients from developing countries often encounter ESBL-producing E. coli in the community through the consumption of contaminated food or water. Considering the rarity at which XDR E. coli isolates are encountered, there is also a scarcity of literature describing the successful treatment of ESBL-producing XDR E. coli. Here we present a case of an otherwise healthy 28-year-old female delicatessen worker infected with ESBL-producing and XDR E. coli without recent travel, antibiotic use, or healthcare contact, who required admission to the intensive care unit (ICU) with pyelonephritis and septic shock. Treatment with intravenous meropenem through a peripherally inserted central catheter (PICC) line at home was curative and follow up thereafter unremarkable. Given the patient’s lack of obvious exposure to and risk factors for an ESBL-producing XDR E. coli infection and the specific lack of risk factors for severe pyelonephritis requiring hospitalization, this case represents a unique addition to the literature and is of value to clinicians by describing successful treatment.

Keywords